

JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants : Hyun-Ah KANG et al. Group Art Unit : 1642
Appl. No. : 10/518,377
(U.S. National Stage of PCT/KR03/001279)
I.A. Filed : June 28, 2003 Examiner : Not Yet Assigned
For : HANSENULA POLYMORPHA YAPSIN DEFICIENT MUTANT STRAIN AND PROCESS FOR THE PREPARATION OF RECOMBINANT PROTEINS USING THE SAME

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and supplemental to the Information Disclosure Statement filed on August 2, 2005, Applicants hereby submit a copy of a European Search Report dated November 2, 2005, with respect to patent family member European Patent Application No. EP 03 73 6354.6, in which the following documents were cited:

- (1) Korean Patent Abstract No. KR 0246932 B1;
- (2) U.S. Patent No. 6,110,703;
- (3) BOURBONNAIS et al., "Production of Full-Length Human Pre-elafin, an Elastase Specific Inhibitor, from Yeast Requires the Absence of a Functional

Yapsin 1(Yap3p)," Protein Expression and Purification, Vol. 20, p.485-491

(2000);

(4) EGEL-MITANI et al., "Yield improvement of heterologous peptides expressed in *yps1*-disrupted *Saccharomyces cerevisiae* strains," Enzyme and Microbial Technology, Vol. 26, pp. 671-677(2000);

(5) International Patent Publication No. WO 00/52133;

(6) KOMANO et al., "Purification and Characterization of the Yeast Glycosylphosphatidylinositol-anchored, Monobasic-specific Aspartyl Protease Yapsin 2 (Mkc7p)," The Journal of Biological Chemistry, Vol. 274, No. 34, pp. 24431-24437 (1999);

(7) CAWLEY et al., "Activation and Processing of Non-anchored Yapsin 1 (Yap3p)," The Journal of Biological Chemistry, Vol. 273, No. 1, pp. 584-591 (1998); and

(8) U.S. Patent No. 5,965,386.

Applicants note that documents (1)-(4) were previously cited in the Information Disclosure Statement filed August 2, 2005. Accordingly, copies of these four documents are not enclosed herewith.

The category of relevance, pertinent portions, and claims to which each document is relevant, as ascertained by the European Examiner, are set forth in the European Search Report.

Further to 37 C.F.R. §1.98 (a)(2)(ii), copies of the U.S. patents are not enclosed herewith. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.

Applicants respectfully request that the Examiner consider the above material and indicate the same. Copies of the above-noted documents are attached hereto and all of the above-noted documents are listed on the attached PTO-1449 Form. The Examiner is requested to initial the appropriate spaces on the attached Form and to return a copy of the completed Form to Applicant with the next official communication in the present application.

Applicants note that an Office Action on the merits has not issued in the present application, and thus no fee is believed necessary to ensure consideration of the submitted material.

Applicants additionally note that documents (1)-(4) were previously cited in an Information Disclosure Statement, and thus, no fee or certification is required to ensure consideration of these materials, as they were already considered. Furthermore, if any fee is necessary for consideration of this Information Disclosure Statement, the undersigned hereby authorizes the charging of any fee necessary for the consideration of this statement, including any payment under 37 C.F.R. §1.17 (p), to Deposit Account No. 19-0089.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,
Hyun-Ah KANG et al.



Bruce H. Bernstein
Reg. No. 29,027



Stephen M. Roylance
Reg. No. 31,296

January 19, 2006
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place]
Reston, VA 20191
(703) 716-11914

FORM PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Doc. No. P26459	Application No. 10/518,377		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Hyun-Ah KANG et al.					
		Filing Date I.A> Filed June 28, 2003		Group 1642			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6 1 1 0 7 0 3	08/29/00	EGEL-MITANI et al.			
		5 9 6 5 3 8 6	10/12/99	KERRY-WILLIAMS et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		0 2 4 6 9 3 2	12/08/99	REPUBLIC OF KOREA			
	0 0 / 5 2 1 3 3		09/08/00	W.I.P.O.			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	English Language Abstract of KR 0246932.					
	2	BOURBONNAIS et al., "Production of Full-Length Human Pre-elafin, an Elastase Specific Inhibitor, from Yeast Requires the Absence of a Functional Yapsin 1(Yap3p)," Protein Expression and Purification, Vol. 20, p.485-491 (2000).					
	3	EGEL-MITANI et al., "Yield improvement of heterologous peptides expressed in <i>yps1</i> -disrupted <i>Saccharomyces cerevisiae</i> strains," Enzyme and Microbial Technology, Vol. 26, pp. 671-677(2000).					
	4	KOMANO et al., "Purification and Characterization of the Yeast Glycosylphosphatidylinositol-anchored, Monobasic-specific Aspartyl Protease Yapsin 2 (Mkc7p)," The Journal of Biological Chemistry, Vol. 274, No. 34, pp. 24431-24437 (1999).					
	5	CAWLEY et al., "Activation and Processing of Non-anchored Yapsin 1 (Yap3p)," The Journal of Biological Chemistry, Vol. 273, No. 1, pp. 584-591 (1998).					
EXAMINER			DATE CONSIDERED				
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							